Adipose-derived Stem Cell Market Key Players Analysis - Allocure, Inc., Celgene Corporation, Pluristem Therapeutics, Inc. (Pluri, Inc), Intrexon, Inc.

Adipose-derived Stem Cell Market worth $ 3013.9 Million by 2030 - Exclusive Report by InsightAce Analytic

InsightAce Analytic Pvt. Ltd. announces the release of a market assessment report on the "Global Adipose-derived Stem Cell Market By Cell type (Autologous and Allogeneic stem cells), Product Type (Cell Line, Culture Media, Media, Sera And Reagents), Disease Conditions (Cancer, Obesity, Wounds And Injuries, Cardiovascular Diseases, Musculoskeletol Diseases And Others), Application (Therapeutic, Research, Others ), End-User (Cell Banks & Tissue Banks, Research Laboratories And Academic institutes, Hospitals and Trauma centers and Other end user industries) -Trends, Industry Competition Analysis, Revenue and Forecast To 2030."

According to the latest research by InsightAce Analytic, the global adipose-derived stem cell market is valued at US$ 1035.13 million in 2021, and it is expected to reach US$ 3013.93 million by 2030, with a CAGR of 13.05% during the forecast period of 2022-2030.

Get Free Access to Demo Report, Excel Pivot and ToC : https://www.insightaceanalytic.com/request-sample/1360

Adipose tissue is now an accessible, plentiful, and stable source for the extraction of adult stem cells appropriate for tissue engineering and regenerative medicine applications. The last decade has seen a boom in preclinical studies on adherent, culture-expanded, adipose-derived stromal/stem cells and newly identified stromal vascular fraction cells, as well as their isolation, characterization, cryopreservation, differentiation, and transplantation in both in vitro and animal models. The healing potential of fat grafting is significantly influenced by the richness of the ADSC. To separate ADSCs from adipose tissue, an isolation technique must be followed, and quality, safety, and efficacy must all be taken into account. ADSCs have been shown to reduce oxidative stress, stimulate revascularization, activate regional stem cell niches, and regulate immunological responses. Because ADSC products can be recovered in large amounts with only limited harm to the donor site, they are appealing regenerative cell therapies. The objective of creating ADSCs suitable for clinical usage becomes increasingly important as their value in clinical contexts increases. A number of nations have implemented regulations to ensure the safety of cell therapies after recognizing the industry's growth.
The market for adipose-derived stem cells is driven by several factors, such as the rise in financing for the research of regenerative therapies and the regulatory approvals for clinical studies of ADSC medications. The establishment of strategic partnerships between manufacturers and research institutes has also recently increased to speed recently upin an effort to speed up the process of finding and isolating novel medications. The process of finding and isolating novel medications.

An infection could result from the introduction of pathogens, viruses, or bacteria that cause disease during the processing stage of adipose-derived stem cell therapy. One possible side effect of adipose-derived stem cell treatment is this. Furthermore, the market's expansion will be constrained by some limitations pertaining to the transportation and storage of the cells.

Over the past ten years, research and development expenditures have been steadily increasing, which is encouraging quick and broad advancements in this therapeutic area.be dominated by North America. past ten years, research and development expenditures have been steadily increasing, which is encouraging for quick and broad advancements in this therapeutic area.

Expert Knowledge, Just a Click Away:https://calendly.com/insightaceanalytic/30min?month=2024-02

Major market players are Allocure, Inc., Celgene Corporation, Pluristem Therapeutics, Inc. (Pluri, Inc), Intrexon, Inc., Celleris SA, Tissue Genesis, Inc., Mesoblast Ltd., Cytori Therapeutics, Antria, Inc., ThermoFisher Scientific, American CrysoStem, Merck KGaA, and Other Prominent players.

Key Developments in the market
• In July 2022, The name change from Pluristem Therapeutics, Inc. to Pluri, Inc. reflects the company's goal of expanding the use of its cutting-edge 3D cell-based technology platform beyond the healthcare sector. Pluri's advanced technology will sustain the advancement of healthcare and pharmaceuticals.
• In Dec 2021, Pluristem and the pharmaceutical company, Innovare R&D teamed up to bring the ARDS programme linked to COVID-19 to Mexico. Innovare will initiate clinical sites and patient enrollment for the proposed clinical study in Mexico under the terms of the agreement. Innovare will provide the funding for the Mexican study and will acquire the PLX cells for the study from Pluristem.
• In Nov 2019, It was announced by Celgene that after the acquisition by Bristol Myers Squibb is finalized, Celgene intends to transfer the listing of its contingent value rights. After the deal was finalized, Celgene became a wholly owned subsidiary of Bristol-Myers Squibb Company, as stated in the merger agreement.
• In Aug 2019, The U.S. FDA approved INREBIC® (Fedratinib) as the first novel therapy for myelofibrosis patients in almost a decade. INREBIC offers patients a novel, once-daily oral treatment alternative for their uncommon bone marrow cancer.

Unlock Your GTM Strategy: https://www.insightaceanalytic.com/customisation/1360

Market Segmentation:
Adipose-derived Stem Cell Market, by Cell Type, 2022-2030 (Value US$ Mn)
• Autologous Stem Cells
• Allogeneic Stem Cells

Adipose-derived Stem Cell Market, by Product Type, 2022-2030 (Value US$ Mn)
• Cell Line
• Culture Media
• Media
• Sera
• Reagents

Adipose-derived Stem Cell Market, by Disease Indication, 2022-2030 (Value US$ Mn)
• Cancer
• Obesity
• Wounds and Injuries
• Cardiovascular diseases
• Musculoskeletal diseases
• Others

Adipose-derived Stem Cell Market, by Application, 2022-2030 (Value US$ Mn)
• Therapeutic
• Research
• Others

Adipose-derived Stem Cell Market, by End-user Industry, 2022-2030 (Value US$ Mn)
• Cell banks & Tissue banks
• Research laboratories and Academic institutes
• Hospitals and Trauma centers
• Others

Adipose-derived Stem Cell Market, by Region, 2022-2030 (Value US$ Mn)
• North America
• Europe
• Asia Pacific
• Latin America
• Middle East & Africa

North America Adipose-derived Stem Cell Market, by Country, 2022-2030 (Value US$ Mn)
• U.S.
• Canada

Europe Adipose-derived Stem Cell Market, by Country, 2022-2030 (Value US$ Mn)
• Germany
• France
• Italy
• Spain
• Russia
• Rest of Europe

Asia Pacific Adipose-derived Stem Cell Market, by Country, 2022-2030 (Value US$ Mn)
• India
• China
• Japan
• South Korea
• Australia & New Zealand

Latin America Adipose-derived Stem Cell Market, by Country, 2022-2030 (Value US$ Mn)
• Brazil
• Mexico
• Rest of Latin America

Middle East & Africa Adipose-derived Stem Cell Market, by Country, 2022-2030 (Value US$ Mn)
• GCC Countries
• South Africa
• Rest of Middle East & Africa

Empower Your Decision-Making with 180 Pages Full Report @ https://www.insightaceanalytic.com/buy-report/1360

About Us:
InsightAce Analytic is a market research and consulting firm that enables clients to make strategic decisions. Our qualitative and quantitative market intelligence solutions inform the need for market and competitive intelligence to expand businesses. We help clients gain competitive advantage by identifying untapped markets, exploring new and competing technologies, segmenting potential markets and repositioning products. Our expertise is in providing syndicated and custom market intelligence reports with an in-depth analysis with key market insights in a timely and cost-effective manner.

Contact us:
InsightAce Analytic Pvt. Ltd.
Visit: www.insightaceanalytic.com
Tel : +1 551 226 6109
Asia: +91 79 72967118
info@insightaceanalytic.com

This release was published on openPR.